Turning Point Starts Trial of Repotrectinib in Pediatric Cancer Patients With Solid Tumors

10:43AM ET 11/12/2019 MT Newswires
Turning Point Therapeutics (TPTX), a precision oncology company, said Tuesday it started a trial of repotrectinib in pediatric cancer patients with ALK-, NTRK- and ROS1-positive solid tumors.

The study is expected to enrol approximately 12 patients in the phase one part, and approximately 63 patients in phase two.

Price: 47.29, Change: +1.31, Percent Change: +2.85